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A B S T R A C T
The fullPIERS model is a risk prediction model developed to predict adverse maternal outcomes within 48 h for women
admitted with pre-eclampsia. External validation of the model is required before implementation for clinical use. We
assessed the temporal and external validity of the fullPIERS model in high income settings using five cohorts collected
between 2003 and 2016, from tertiary hospitals in Canada, the United States of America, Finland and the United
Kingdom. The cohorts were grouped into three datasets for assessing the primary external, and temporal validity, and
broader transportability of the model. The predicted risks of developing an adverse maternal outcome were calculated
using the model equation and model performance was evaluated based on discrimination, calibration, and stratifica-
tion. Our study included a total of 2429 women, with an adverse maternal outcome rate of 6.7%, 6.6%, and 7.0% in the
primary external, temporal, and combined (broader) validation cohorts, respectively. The model had good dis-
crimination in all datasets: 0.81 (95%CI 0.75–0.86), 0.82 (95%CI 0.76–0.87), and 0.75 (95%CI 0.71–0.80) for the
primary external, temporal, and broader validation datasets, respectively. Calibration was best for the temporal cohort
but poor in the broader validation dataset. The likelihood ratios estimated to rule in adverse maternal outcomes were
high at a cut-off of ≥30% in all datasets. The fullPIERS model is temporally and externally valid and will be useful in
the management of women with pre-eclampsia in high income settings although model recalibration is required to
improve performance, specifically in the broader healthcare settings.
1. Introduction
Pre-eclampsia and other hypertensive disorders of pregnancy
(HDPs) remain a significant cause of maternal and fetal morbidity and
mortality, globally [1,2]. Severe maternal morbidities resulting from
pre-eclampsia include stroke, eclampsia and liver dysfunction [3].
Presently, delivery is the only cure; however, this is not always the best
option for the fetus if the delivery occurs preterm [1]. While expectant
management has been proposed as a means to achieve improved fetal
survival, it is unclear for how long to delay delivery and how high the
resultant risk is for the mother [4,5]. Accurate prognosis in women with
pre-eclampsia and other HDPs is necessary to support a practice of
expectant management and guide clinical decisions for timing of de-
livery, administration of antenatal corticosteroids and magnesium sul-
phate, or transfer to a higher level of care.
The fullPIERS (Pre-eclampsia Integrated Estimate of RiSk) model was
developed to predict adverse maternal outcomes resulting from pre-
eclampsia. The study’s primary adverse maternal outcome was defined as
one or more of the pre-specified severe maternal complications, which
included central nervous system (CNS), hepatic, renal, cardiovascular
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and respiratory outcomes, occurring within 48 h of a woman’s admission
for pre-eclampsia (full definitions listed in Table S1) [6]. The rationale
behind the PIERS project was that correctly identifying an individual
woman’s risk of complications before they happen would improve the
clinician’s ability to counsel that woman on timing of delivery and use of
other interventions and avoid those complications. The multivariable
model was developed in 2010 using a cohort of 2023 women admitted in
tertiary centres in high income countries (HICs) with a 5% rate of ad-
verse maternal outcomes. All the participating hospitals had expectant
management policies for pre-eclampsia. Six predictor variables were in-
cluded in the model: gestational age, chest pain or dyspnoea, oxygen
saturation (SpO2), platelet count, serum creatinine, and serum aspartate
transaminase. The fullPIERS model was internally validated and had
excellent discriminatory performance, with an area under the receiver-
operating characteristic curve (AUROC) of 0.88 (95% confidence interval
[CI], 0.84–0.92). The fullPIERS model equation is shown in Box 1. Al-
though the model has promising predictive performance, temporal and
external validation are necessary before it can be recommended for
clinical use [7,8]. Validation ascertains the accuracy of the model in the
population that it was designed for based on discriminatory and cali-
bration performance. Temporal validation is carried out in the same
setting as the one used during model development but with more recent
patients, thereby prospectively evaluating model performance. External
validation involves assessments in a similar population to that used for
model development in other settings. Geographical validation is a type of
external validation that includes cases that have the same inclusion and
exclusion criteria as the development setting [8,9].
Although there have been a few attempts to externally validate the
fullPIERS model, none of the studies conducted have used a similar
patient populations and healthcare settings as the development popu-
lation. Differences include use of data from low-and-middle-income
countries (LMIC) [10,11] or using a subset (less than 34weeks’ gesta-
tional age) or broader inclusion criteria for disease (all HDPs). In ad-
dition, inadequate sample size has been an issue limiting the conclu-
sions that can be drawn from these studies.[12] Using a sufficient
sample size, we sought to assess geographic external- and temporal-
validity of the fullPIERS model using datasets collected in high income
countries with similar populations.
Box 1
The fullPIERS Logistic Regression Equation for the prediction
of adverse maternal outcomes from pre-eclampsia: logit
(pi)= 2·68+ (−5·41× 10−2; gestational age at elig-
ibility)+ 1·23(chest pain or dyspnoea)+ (−2·71× 10−2;
creatinine)+ (2·07×10−1; platelets)+ (4·00×10−5; plate-
lets2)+ (1·01× 10−2; aspartate trans ami-
nase)+ (−3·05× 10−6; AST2)+ (2·50× 10−4; creati-
nine× platelet)+ (−6·99× 10−5; platelet× aspartate
transaminase)+ (−2·56×10−3; platelet× SpO2)
2. Methods
2.1. Ethics
This study was approved by the University of British Columbia
ethics board (CREB no: H07-02207).
2.2. Study population
2.2.1. Development cohort
The fullPIERS model was developed using data collected from high-
income countries: Australia, Canada, New Zealand and the United
Kingdom (UK). Data were collected prospectively from 2023 women
admitted to a participating tertiary level facility with pre-eclampsia
from July 2008 to January 2011. Pre-eclampsia was defined as hy-
pertension with proteinuria or hyperuricaemia, or HELLP (Haemolysis
Elevated Liver enzymes Low Platelet count) syndrome [6]. The study’s
primary adverse maternal outcome was a pre-specified composite of
severe maternal complications occurring within 48 h of hospital ad-
mission. These outcomes were agreed upon using a Delphi consensus
process prior to the model development study [6]. A full list of the
outcomes is listed in Appendix S1 and a fullPIERS calculator online
(https://pre-empt.cfri.ca/monitoring/fullpiers) and. Women were ex-
cluded from the cohort if they had already experienced an adverse
maternal outcome before hospital admission and data collection or if
they were admitted in spontaneous labour. Further details of the full-
PIERS cohort have been described elsewhere [6].
2.2.2. Temporal and external validation datasets
We identified five cohorts for the temporal and external validation of
the fullPIERS model. The decision to use these cohorts in our study was
based on the cohorts having similar participant inclusion and exclusion
criteria, and being derived in a similar tertiary unit health care setting.
The data included were collected from the (i) British Columbia Women’s
(BCW) Hospital (ii) the Finnish Genetics of Preeclampsia Consortium
(FINNPEC) study (iii) Pre-EcLampsIa: Clinical ApplicatioN (PELICAN) of
PlGF study (iv) Alere-funded Pre-Eclampsia Triage by Rapid Assay
(PETRA) study and, (v) John Radcliffe Hospital, Oxford (Oxford).
The BCW cohort was made up of data extracted from retrospective
medical chart reviews for women admitted with pre-eclampsia to the
BCW’s Hospital (Vancouver, Canada) from January 2012 to May 2016.
This site was one of the centres involved in the development of the
fullPIERS model. The FINNPEC study recruited a cross-sectional, case–-
control cohort of singleton pregnancies from five university hospitals in
Finland during 2008–2011.[13] The prospective PELICAN cohort in-
cluded women who presented with symptoms or signs of suspected pre-
eclampsia at one consultant-led maternity unit in the UK, January 2011
to February 2012 [14]. The BCW, FINNPEC and PELICAN cohorts centres
practised expectant management for pre-eclampsia, similar to the centres
involved in the development of the fullPIERS model. The PETRA cohort
included women with symptoms and signs of pre-eclampsia presenting at
twenty-four maternity units in the United States of America (USA) and
Canada [15]. This was a prospective, observational cohort and women
were recruited between January 2011 and February 2012; however, an
interventionist management policy was more common in the Alere-
PETRA centres. Finally, for the Oxford cohort, data were extracted ret-
rospectively from the hospital flow sheets of women admitted in the
Silver Star unit of John Radcliffe Hospital, Oxford, from 2003 to 2006.
For this study we used three sets of validation data: (i) the primary
external data, comprising of the BCW, FINNPEC, and PELICAN cohorts,
(ii) the temporal validation data, comprising of the BCW cohort only (iii)
and the broader external data comprising of all five cohorts i.e., the BCW,
FINNPEC, PELICAN, PETRA and Oxford cohorts. We divided the external
validation into two sections – primary external validation using datasets
with similar expectant management policies and data collection as that
used during fullPIERS model development (to assess the reproducibility
of the model in the most similar and reliable datasets) and “broader”
external validation using combined datasets (to assess the overall
transportability of the model) due to differences in clinical practice and
data completeness. We planned a priori to base our interpretation of the
model performance on the primary external dataset results. In addition,
we assessed the model in only the BCW cohort for temporal validation
because it was one of the model development sites.
2.3. Definition of pre-eclampsia and outcomes
We used the same definitions for pre-eclampsia as used in the
fullPIERS model development study, as described above.
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The primary outcome in our validation study was also the same as in
the model development study (Table S1). When the exact time of day of
the occurrence of an outcome was unknown, we used outcomes oc-
curring within two calendar days from the date of admission as a proxy
for adverse maternal outcomes occurring within 48 h. We examined
outcomes occurring within seven days as a secondary outcome.
2.4. Statistical analyses
2.4.1. Demographics
The distribution of patient characteristics of the five cohorts in-
cluded in the three validation sets were compared with the develop-
ment (fullPIERS) cohort. Univariate comparisons of characteristics of
women who experienced an adverse outcome and those who did not,
were also performed for each validation data set.
2.5. Model performance evaluation
Using the worst value of each predictor measured within 48 h of
admission prior to the occurrence of an adverse outcome, the published
fullPIERS equation was applied to each of the validation datasets to
calculate the predicted probability of experiencing an adverse outcome
for each woman in the cohort under study. The performance of the
model was evaluated based on its discrimination, calibration and stra-
tification capacity.
Discriminative ability was assessed using the AUROC and was in-
terpreted using the following pre-specified criteria: non-informative
(AUROC≤0·5), poor discrimination (0.5 < AUROC < 0·7), good
discrimination (AUROC≥0·7) [7,16]. Calibration was assessed by es-
timating the slope on a calibration plot of predicted versus observed
outcome rates in each decile of predicted probability; a calibration
slope of 1 and intercept of 0 is considered ideal [7]. Similar to the
AUROC, a calibration slope was interpreted as: non-informative
(slope≤0·5), poor calibration (0.5 < slope < 0·7) and good calibra-
tion (slope≥ 0·7) [17,18]. The stratification capacity of the model to
classify the women into low- and high- risk categories was assessed
using a classification table with generated risk groups (defined based on
categories established in the model development study) [17,18]. The
true and false positive rates, negative predictive values (NPVs), and
positive predictive values (PPVs) were computed for each group. The
Likelihood Ratios (LRs) were calculated for each group using the Deeks
and Altman method for a multi-category diagnostic test [19].
2.5.1. Sensitivity analyses
For sensitivity analyses, we assessed the model performance in the
validation cohorts for the prediction of adverse outcomes occurring
within seven days of admission as done in the model development. This
was done to evaluate the model’s clinical utility within a longer time
frame. Secondary analyses also included assessment of the discrimina-
tion capacity of the (i) primary and (ii) combined external validation
data without the BCW’s Hospital cohort. This was done to validate the
inclusion of BCW data in all our analyses subsets.
2.5.2. Missing data
Missing SpO2 was substituted with the median of 97%, as done
during the fullPIERS model development [6]. If missing, AST was
substituted with alanine transaminase (ALT) when available, as this
measurement had been agreed to be biologically similar by expert
opinion. For other variables or where both AST and ALT were absent,
the type of missingness was explored by comparing cases with and
without missing data in the validation cohorts, and multiple imputa-
tions were used to generate plausible values for missing variables.
Multiple imputation was carried out ten times using the multiple im-
putation by chained equations (MICE) method [20–22].
2.5.3. Sample size
Our sample size was based on simulation studies which recommend
80–100 events (outcomes) and 100 non-events for sufficient power in
validation studies [12]. This number of events was calculated to give
80% power at the 5% significance level. This was used to determine
adequate statistical power in our study.
All statistical analyses were performed using R version 3·1·3 (The R
Project for Statistical Computing).
3. Results
3.1. Comparison of the development and validation cohorts
In total, the combined cohort was made up of 2429 women: BCW
(N=1310), FINNPEC (N=124), PELICAN (N=70), PETRA
(N=644) and Oxford (N=281). The distribution of patient char-
acteristics between the development and individual validation cohorts
are presented in Table 1. Compared to the development cohort, the
women in the BCW cohort were more likely to be older, have a later
onset of pre-eclampsia, and higher AST; the FINNPEC cohort was least
likely to be multiparous and have more symptoms of chest pain or
dyspnoea, while the PELICAN cohort had the lowest rate of smoking,
and higher uric acid measurements. Compared to the development
cohort, the women in the PETRA cohort were more likely to have an
earlier onset of pre-eclampsia, had a higher rate of smoking, lower
corticosteroid use for early onset pre-eclampsia but higher use of
magnesium sulphate, and shorter admission to delivery for women with
gestational age less than 34weeks; they also had lower birth weights.
The women in the Oxford cohort had higher platelets and creatinine
measurements compared to the development cohort.
The combined distribution of patient characteristics for the cohorts
grouped according to their analytical use (validation datasets), com-
pared with the development cohort, are presented in Table S2. In total,
the primary external, temporal validation and broader cohorts included
1504, 1310, and 2429 women respectively. Compared to the develop-
ment cohort, the women in the primary external datasets were more
likely to have an earlier onset of pre-eclampsia and less likely to smoke,
while the women in the broader external datasets were more likely to
multiparous and administered MgSO4. The women in both the primary
and broader external datasets were more likely to be older, compared to
the development cohort.
Within 48 h of admission, the rates of adverse maternal outcomes
encountered in the temporal, primary, and broader external validation
cohorts were 87 (6.6%), 99 (6.7%) and 171 (7.0%), respectively. The
rates of adverse maternal outcomes occurring within seven days or at
any time during admission and the rates of stillbirths or neonatal deaths
were similar between the validation and the development cohorts
(Table S2).
Table S3 presents the individual components of the primary com-
posite adverse outcome that occurred within 48 h of admission. The
most common outcomes in combined validation cohorts were blood
transfusion (N=61), placental abruption (N=21), and infusion of a
third antihypertensive medication (N=21). There were no cases of
maternal deaths, cortical blindness or hepatic rupture.
3.2. Women with and without outcomes
In all the validation cohorts, women with an adverse maternal
outcome within 48 h had an earlier onset of pre-eclampsia, worse
clinical measures (i.e. higher chest pain, sBP, uric acid, and lower
platelet count) and more interventions (antihypertensive and magne-
sium sulphate treatment) (Table S4). They also delivered at an earlier
gestational age with babies of lower birth weights. These characteristics
were similarly observed in the development cohort.[6]
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3.3. Data completeness
Table S5 shows the number of missing predictor variables in each of
the analysis/validation cohorts. Gestational age at admission for disease
was the most complete variable in all the validation datasets except for
two missing cases (0.1%) in the broader external dataset while chest
pain/dyspnoea and SpO2 had the highest proportion of missing data.
The broader validation dataset had the most missingness overall with
3.3% for platelet count, 4.5% for AST or ALT, 7.3% for serum creati-
nine, 37.2% for chest pain or dyspnoea, and 42.4% for SpO2.
3.4. Model performance
3.4.1. Primary external validation
The fullPIERS model showed good discrimination in the primary
external validation dataset with an AUROC of 0.81 (95% CI 0.76–0.87)
(Fig. 1a). Imputation of missing variables did not show any significant
change in the discriminatory performance (AUROC of 0.81 (95% CI
0.75–0.86).
The model also showed good calibration performance in the pri-
mary external validation dataset with a slope of 0.70, although the
intercept was marginally elevated (α = 0.3) (Fig. 2a).
Table 2 shows the distribution of women in pre-specified predicted
probability risk groups and the stratification capacity of the model in
each group for the primary external validation dataset. The distribution
of women in these risk group was similar to the model development
study with 30.5% of women having a predicted probability of< 1%
(35% in the development cohort) and 4% of women with a predicted
probability of ≥30% (also 4% in the development cohort) [6]. Using
the predicted probability cut-off of ≥30% for high risk (pre-identified
threshold in the model development study), 55% of the women had an
adverse outcome. The resulting false positive rate was 2% (specificity of
98%) and the true positive rate (sensitivity) was 36% with a high LR of
17 (95%CI 10.97–26.43) showing strong evidence to rule in adverse
maternal outcomes; the LR at the lower predicted scores (< 2.5%) were
not useful for ruling out adverse outcomes. Overall, the model was able
to stratify women into a high risk group (predicted probability ≥30%)
and a low risk group (predicted probability< 30%).
3.4.2. Temporal validation
For the temporal validation using only the BCW cohort, the
fullPIERS model showed good discrimination capacity with an AUROC
of 0.82 (95% CI 0.76–0.87) (Fig. 1c), which did not change after im-
putation of missing values. Calibration was good with a slope of 0.70
and intercept of 0.20 (Fig. 2b).
Table 3 presents the distribution of women and the stratification
capacity of the model in the temporal validation datasets in each pre-
specified predicted risk group. The proportions of women in the lowest
(< 1%) and highest risk group (≥30%) were 30% and 5% respectively.
The proportion of women with adverse outcomes in the highest risk
group of≥ 0.3 (56%) was also similar to the proportion in the devel-
opment data (59%).[6] The resulting false positive rate was 2% (spe-
cificity 98%) and the true positive rate was 41% with a high LR of 18
(95%CI 11.60–28.16) at this threshold, showing strong evidence to rule
in adverse maternal outcomes.
Table 1
Maternal characteristics for the individual validation datasets and development dataset.
Characteristics fullPIERS cohort
(development) (2023 women)
BCW (1310 women)
(Also Temporal)
FINNPEC
(124 women)
PELICAN
(70 women)
PETRA
(644 women)
Oxford (2 8 1)
DEMOGRAPHICS & PREGNANCY
CHARACTERISTICS
Maternal age at EDD (yr) 31 [27,36] 34 [31,38] 31 [27, 34] 33 [29, 38] 30 [24, 34] 32 [28, 36]
Parity≥ 1 581 (28·7%) 409 (31.2%) 25 (20.2%) 31 (44.3%) 280 (43.5%) 127 (45.2%)
Gestational age at eligibility (wk)** 36 [33, 38·3] 37.7 [35.6, 39] 35.2 [31.4, 37·0] 35.8 [34.3, 38.0] 33.9 [30.3, 36.3] 36.7 [33.7, 38.3]
Gestational age at eligibility < 34weeks, N 636 (31.4%) 218 (16.6%) 51 (41.1%) 16 (22.9%) 331 (51.4%) 99 (35.2%)
Multiple pregnancy 192 (9·5%) 136 (10.4%) 0 5 (7.1%) 52 (8.1%) 26 (9.3%)
Smoking in this pregnancy 249 (12·3%) 90 (6.9%) 15 (12.1%) 2 (2.9%) 140 (21.7%) 23 (8.2%)
CLINICAL MEASURES
Systolic BP (mm Hg) 160 [150, 176] 160 [151, 171] 169 [158, 179] 157 [150, 170] 143 [133, 154] 150 [140, 160]
Diastolic BP (mm Hg) 102 [98, 110] 100 [94, 105] 104 [99, 110] 98 [92, 102] 84 [76, 93] 98 [90, 101]
Chest pain/dyspnoea** 90 (4.4%) 82 (6.3%) 10 (8.1%) 3 (4.3%) 13 (2.0%) 7 (2.5%)
Uric acid (µM) 376 [320, 427] 379 [323, 436] 366 [323, 423] 400 [325, 495] 369 [309, 428] 337 [271, 390]
Lowest platelet count (×109 per L)** 192 [150, 242] 174 [136, 217] 187 [153, 232] 170 [128, 212] 203 [158, 248] 225 [178, 275]
Highest AST/ALT (U/L)** 28 [21, 41] 33 [26, 47] 19 [14, 30] 20 [14, 32] 23 [18, 34] 17 [13, 27]
Creatinine (µM) 67 [58, 77] 64 [56, 75] 62 [54, 69] 70 [59, 84] 61 [53, 71] 75 [68, 84]
INTERVENTIONS DURING ADMISSION
Corticosteroids 550 (27·2%) 320 (24.4%) 56 (45.2%) 31 (44.3%) 161 (25.0%) 78 (27.8%)
Corticosteroids, GA onset < 34 440/636 (69.2%) 195/218 (89.5%) 43/51 (84.3%) 14/16 (87.5%) 137/331 (41.4%) 65/99 (65.7%)
Antihypertensive therapy 1381 (68·3%) 896 (68.4%) 104 (83.9%) 58 (82.9%) 463 (71.9%) 175 (62.3%)
MgSO4 690 (34·1%) 393 (30.0%) 69 (55.7%) 11 (15.7%) 464 (72.1%) 31 (11.0%)
PREGNANCY OUTCOMES
Admission-To-Delivery Interval (Days) 2 [1, 5] 1 [1, 3] 4 [2,7] 6 [3, 14] 2 [1, 4] 3 [1, 8]
Admission-To-Delivery Interval, < 34+0
Weeks (Days)
4 [2, 14] 4 [2, 11] 6 [3, 8] 13 [8, 26] 3 [1, 6] 8 [4, 19]
Gestational age at delivery (wk) 36.9 [34·1, 38·6] 37.8 [36, 39.1] 35.9 [32.3, 37.9] 37.6 [36.3, 38.3] 34.6 [31.1, 36.9] 36.7 [33.7, 38.3]
Birth weight (grams) 2141
[1441, 2807]
2885
[2275, 3364]
2305
[1475, 2930]
2700
[2065, 3150]
2070
[1286, 2770]
2516
[1647, 3216]
Stillbirth 20 (1.0%) 7 (0.5%) 0 0 10 (1.6%) 8 (2.9%)
Neonatal death 26 (1·3%) 10 (0.8%) 1 (0.8%) 0 13 (2.0%) 25 (8.9%)
MATERNAL OUTCOME(N women)
Within 48 h 106 (5.2%) 87 (6.6%) 11 (8.9%) 1 (1.4%) 48 (7.5%) 24 (8.5%)
Within 7 days 203 (10.0%) 110 (8.4%) 40 (32.3%) 2 (2.9%) 56 (8.7%) 45 (16.0%)
At anytime 261 (12.9%) 122 (9.3%) 62 (50.0%) 6 (8.6%) 62 (9.6%) 57 (20.3%)
AST (aspartate aminotransferase), BP (blood pressure), EDD (estimated date of delivery), MgSO4 (magnesium sulphate).
**Variables included in the model.
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3.4.3. Broader external validation
The fullPIERS model retained good discrimination in the broader
validation dataset although the AUROC decreased (0.74 (95% CI
0.69–0.80) (Fig. 1c). As seen in the prior validation cohorts, there was
also no significant change after imputation of missing data (AUROC of
0.75 (95% CI 0.71–0.80). Calibration ability was poor with a slope of
0.55 and intercept of 0.30 (Fig. 2c).
Similar to the primary external validation dataset, about 4% of
women had a predicted probability of ≥30% (Table 4) [6]. In this
highest risk group, half of women had an adverse outcome. The re-
sulting false positive rate was 2% (specificity 98%) and the true positive
rate was 27% with a LR of 13 (95% CI 9.21–18.9).
Thus, the LR also showed strong evidence to rule in adverse ma-
ternal outcomes in all datasets.
3.5. Sensitivity analyses
3.5.1. Performance for outcomes within seven days
Model performance decreased in all three validation datasets for the
prediction of adverse outcomes within seven days. The AUROCs after
imputation of missing data were 0.71 (95% CI 0.66–0.76), 0.69 (95% CI
0.65–0.73), and 0.78 (95% CI 0.72–0.83), for the primary external,
broader and temporal validation datasets, respectively. Calibration was
poor in all datasets with slopes of 0.63, 0.61 and 0.44 for the temporal,
primary external and broader external datasets, respectively. Similar
results were observed from the complete case analyses.
3.5.2. Performance of model excluding the BCW cohort
The discriminatory performance of the model dropped in both the
primary and broader external validation datasets upon the exclusion of the
BCW’s cohort, although the AUROCs remained>0.70 (Appendix Fig. 1).
4. Discussion
We assessed the temporal and external validation of the fullPIERS
model using three datasets from high income countries for the prediction
of adverse maternal outcomes within 48 h. Overall, the model retained
good discriminatory performance across all datasets (AUROC≥0.7).
Calibration was good in the primary and temporal external datasets but
was poor in the broader external dataset, as reflected by the reduction in
slope. An increase in the calibration intercept was also observed in all
three of the validation cohorts. Despite errors in calibration the model
was able to classify women into low- and high-risk groups using a pre-
dicted probability cut-off of ≥30% and showed a strong ability to ‘rule
in’ adverse outcomes within 48 h at this cut-off.
In external validation studies, decreases in model performance are
common and can be a result of overfitting of the model to the data used
for development, case-mix differences between the development and
validation cohorts, or differences in the effect of the model predictors
between the development and validation cohorts, or a combination of
some or all of these factors [8]. All the AUROCs estimated in the three
validation cohorts were lower than that estimated in the original full-
PIERS model development study (0.88 (95% CI 0.84–0.92). This dif-
ference was only significant in the broader validation cohort (the
confidence intervals overlapped for the primary external and temporal
Fig. 1. Discrimination performance of the fullPIERS model within 48 h of admission.
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validation). A decrease in performance was also observed in the cali-
bration ability of the model upon temporal validation, whereby the
dataset most similar to the development cohort was used.
There were fewer case-mix differences between the development
and temporal validation data with regard to demographics, anti-
hypertensive administration, and adverse neonatal and maternal out-
comes (Table 1). Despite the fact that the women in the temporal cohort
had worse predictor measurements, the rates of adverse outcomes be-
tween the two cohorts were similar, suggesting a possible difference in
the predictor-outcome relationship. Studies have reported that a
slope < 1 is indicative of inconsistent predictor effects or/and
overfitting [7,23]. We suspect that it is more likely that the reduced
performance was due to different predictor effects and perhaps, over-
fitting than due to case-mix differences [9,23].
In addition to the predictor-effects, case-mix differences may have
played a more substantial role in the broader external dataset, as there
were more differences in population characteristics observed in the
PETRA and Oxford datasets compared to the fulPIERS cohort. There
was also a slightly higher rate of adverse maternal outcome within 48 h,
which was reflected in the calibration intercept (0.3). Of note, the
PETRA cohort, which significantly contributed to the broader valida-
tion dataset, primarily included women admitted in the USA. The
Fig. 2. Calibration performance of the fullPIERS model within 48 h of admission.
Table 2
Risk stratification table to assess the performance of the fullPIERS model for predicting maternal outcome at varying predicted probability cut-off values within 48 h
in the Primary External Validation dataset.
Prediction score range
(Mean predicted
probability)
Total N women in
range (%) (N=1504)
N women with
outcome (%
(N=99)
LR [95% CI] NPV (%)
[95% CI]
PPV (%)
[95% CI]
*True positive rate
(%) [95% CI]
False positive rate
(%) [95% CI]
<1.0%
(0.5%)
459 (30.5%) 8 (1.7%) 0·25
[0·12–0.52]
– – – –
1·0–2·4%
(1.2%)
498 (33.1%) 14 (2.8%) 0·41
[0·25–0.67]
98
[0·96–0·99]
8.6
[0·07–0·11]
92
[0·84– 0·96]
68
[0·65–0·70]
2·5–4·9%
(3.4%)
287 (19.1%) 13 (4.5%) 0·67
[0·40–1.13]
98
[0·96–0·99]
14
[0·11–0·17]
78
[0·68–0·85]
34
[0·31– 0·40]
5·0–9·9%
(7.0%)
117 (7.8%) 16 (13.7%) 2.25
[1.38–3.66]
97
[0·96–0·98]
25
[0·20–0·31]
65
[0·54–0·74]
14
[0·12–0·16]
10·0–29·9%
(17.2%)
77 (5.1%) 12 (15.6%) 2.62
[1.47–4.68]
96
[0·95–0·97]
47
[0·36–0·58]
41
[0·32–0·52]
7
[0·06–0·08]
≥30·0%
(60.9%)
66 (4.4%) 36 (54.5%) 17.03
[10.97–26.43]
96
[0·94–0·97]
55
[0·42–0·67]
36
[0·27–0·47]
2
[0·02–0·03]
LR, Likelihood ratios; PPV, positive predictive value; NPV, negative predictive value.
*True positive rate (or Sensitivity), false positive rate (1-Specificity).
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pattern of practice for the management of women with pre-eclampsia in
the USA is different from the other datasets in that it is more inter-
ventionist than expectant; this could also be observed from the short
admission to delivery interval for women with gestational age less than
34 weeks compared to the other cohorts (Table 1). Earlier delivery
would shorten the natural course of pre-eclampsia and could reduce
performance of the model. The extreme predictions shown in the cali-
bration graph (over-prediction of outcomes in the lower risk groups and
under-prediction in the higher risk groups) as well as the significant
reduction in slope (0.55) are also suggestive of overfitting of the model
[9]. These findings suggest a need for recalibration of the model to
improve its performance in broader external dataset.
4.1. Comparison with existing literature
Four previous studies have assessed the validity of the fullPIERS
model [10,11,24]. The study by Akkermans et al. [24]. used a cohort of
women with severe, early-onset pre-eclampsia admitted into tertiary
centres in the Netherlands. Although this study included patients from a
similar setting to the fullPIERS cohort i.e. tertiary, high income setting,
their inclusion criteria may have resulted in a significant case-mix
difference. In contrast with our study, they reported a higher dis-
criminative performance of the model (AUC ROC 0.97, 95% CI:
0.94–0.99). The validation studies by Agrawal et al. [10] and Ukah
et al. [11] both examined the fullPIERS model in low resourced settings
and the study by Hadley et al. [25] included women with all HDPs. The
use of datasets with populations from low-and-middle income settings
(less resources and higher rates of outcomes), or with different inclu-
sion criteria (e.g. other types of HDPs were included), and different
management practice (e.g. less expectant management), compared to
the development cohort, may have also contributed to an increase in
severity of case-mix and resulted in the lower performance reported by
these studies. Similar to our study; these three studies [10,11,25] re-
ported a decrease in discriminative ability (although all three studies
still reported good discrimination AUROC > 0.7).
4.2. Strengths and limitations
A strength of this study is the assessment of the validity and
transportability of the fullPIERS risk prediction model using data si-
milar to the model development cohort i.e. data from tertiary and high-
income settings. We also had sufficient power to detect any major
changes in the model performance. The findings from our analyses are
important to actually determine if the model itself is valid as developed,
and not just if it works by chance or due to peculiarities in the vali-
dation cohort used. The combination of cohorts from different sites also
makes our findings more generalizable; thus our findings represent a
true validation of the model’s performance in similar settings.
Table 3
Risk stratification table to assess the performance of the fullPIERS model for predicting maternal outcome at varying predicted probability cut-off values within 48 h
in the temporal dataset.
Prediction score
range
Total N women in range
(%) (N=1310)
N women with
outcome (%)
(N=87)
LR [95% CI] NPV (%)
[95% CI]
PPV (%)
[95% CI]
*True positive rate
(%) [95% CI]
False positive rate (%)
[95% CI]
<1.0%
(0.6%)
395 (30.2%) 6 (1.5%) 0·22
[0·09–0·50]
– – – –
1·0–2·4%
(1.2%)
430 (32.8%) 11 (2.6%) 0·37
[0·21–0·64]
98
[0·97–0·99]
8.9
[0·07–0·11]
93
[0·85– 0·97]
68
[0·66–0·70]
2·5–4·9%
(3.4%)
247 (18.9%) 11 (4.5%) 0·66
[0·37–1.51]
98
[0·97–0·99]
14
[0·12–0·18]
80
[0·70–0·88]
34
[0·31– 0·37]
5·0–9·9%
(7.0%)
109 (8.3%) 14 (12.8%) 2.07
[1.24–3.47]
97
[0·96–0·98]
25
[0·20–0·31]
68
[0·57–0·77]
15
[0·13–0·17]
10·0–29·9%
(16.9%)
65 (5.0%) 9 (13.8%) 2.26
[1.16–4.41]
96
[0·95–0·97]
48
[0·37–0·59]
45
[0·34–0·56]
7
[0·06–0·08]
≥30·0%
(61.5%)
64 (4.9%) 36 (56.3%) 18.07
[11.60–28·16]
96
[0·95–0·97]
56
[0·43–0·68]
41
[0·31–0·52]
2
[0·02–0·03]
LR, Likelihood ratios; PPV, positive predictive value; NPV, negative predictive value.
*True positive rate (or Sensitivity), false positive rate (1-Specificity).
Table 4
Risk stratification table to assess the performance of the fullPIERS model for predicting maternal outcome at varying predicted probability cut-off values within 48 h
in the Broader (Combined) dataset.
Prediction score
range
Total N women in range
(%) (N=2429)
N women with
outcome (%)
(N=171)
LR [95% CI] NPV (%)
[95% CI]
PPV (%)
[95% CI]
*True positive rate
(%) [95% CI]
False positive rate (%)
[95% CI]
<1%
(0.6%)
604 (24.9%) 14 (2.3%) 0·31
[0·18–0·55]
– – – –
1·0–2·4%
(1.7%)
779 (32.1%) 27 (3.5%) 0·47
[0·34–0·66]
98
[0·96–0·99]
8.6
[0·07–0·10]
92
[0·86– 0·95]
74
[0·72–0·76]
2·5–4·9%
(3.5%)
526 (21.7%) 31 (5.9%) 0·83
[0·61–1.12]
97
[0·96–0·99]
12
[0·11–0·15]
76
[0·69–0·82]
41
[0·39– 0·43]
5·0–9·9%
(7.0%)
259 (10.7%) 30 (11.6%) 1.73
[1.25–2.40]
96
[0·95–0·97]
19
[0·16–0·23]
58
[0·50–0·65]
19
[0·17–0·20]
10·0–29·9%
(16.3%)
169 (7.0%) 23 (13.6%) 2.08
[1.40–2.09]
95
[0·94–0·96]
26
[0·21–0·32]
40
[0·33–0·48]
9
[0·07–0·10]
≥30·0%
(60.4%)
92 (3.8%) 46 (50.0%) 13.20
[9.21–18.9]
95
[0·94–0·96]
50
[0·39–0·61]
27
[0·21–0·34
2
[0·02–0·03]
LR, Likelihood ratios; PPV, positive predictive value; NPV, negative predictive value.
*True positive rate (or Sensitivity), false positive rate (1-Specificity).
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One limitation is that to achieve adequate power, we included
women from BCW’s Hospital, which was one of the development sites,
in the primary and broader external validation datasets. Although it
may be ideal to use completely different sites for an external validation,
these women were enrolled in a later time period from those used in the
development study and can still be considered an external cohort. Our
sensitivity analyses assessing the impact of including the BCW cohort
demonstrated that the discriminatory performance without the BCW
cohort remained good (AUROC > 0.70) showing that the model per-
formance was not entirely dependent on the BCW cohort.
Another limitation was the large percentage of missing data in the
broader external validation dataset. Although we accounted for this
limitation by using multiple imputation techniques, these may have
affected the precision of the model performance estimate. However,
research suggests that imputation is preferable to omission of in-
dividuals, even if a predictor is completely missing in a dataset [22,26].
Our imputation analyses did not show any significant difference,
thereby suggesting that there was less likelihood of bias in the broader
external datasets. We hope that our results will encourage the mea-
surements of SpO2 and other model variables since they are important
predictors of adverse maternal outcomes within 48 h.
4.3. Implications for clinical practice
This external validation study shows that the fullPIERS model is
useful in discriminating between patients at high and low risk of ad-
verse maternal outcomes within 48 h and even up to a week after as-
sessment. Our study also shows that using a threshold of ≥30% pre-
dicted probability was a good threshold to rule-in the outcome. Based
on our results, the model can be used to aid clinicians in managing
women with pre-eclampsia in similar settings and to make decisions
such as transfer to higher care units and delivery. However, caution
should be applied when using the model in settings with a broader case-
mix of patients or a more interventionist management style such as
those participating in the PETRA study. Recalibration of the model
should be considered in these settings before clinical use.
5. Conclusion
The fullPIERS model is temporally and externally valid for the predic-
tion of adverse maternal outcomes occurring within 48h of admission for
pre-eclampsia. Recalibration might be helpful in improving the calibration
performance in more diverse settings. Future studies should focus on re-
calibration and assessing the model performance in broader sub-groups.
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